Foundation Medicine Rebrands Saga Diagnostics MRD Test, Seeks New Indications
Summary
Foundation Medicine is rebranding its Saga Diagnostics MRD test and planning to expand its clinical use into new indications. The update points to continued development of a software- and data-enabled life sciences offering tied to minimal residual disease testing. This kind of move can widen the commercial scope of the product and support broader adoption in oncology workflows. The article text provided is limited, so the key takeaway is the product repositioning and indication expansion effort.
Classifications
industries
HealthTech
applications
Business Intelligence
AskAI Classifications
Labels
SaaS
Healthcare Analytics Software
Bioinformatics Software
